Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 3/20 | 0.43 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401661 | 1.00 | CASP3 (0.51) | CASP3ITGB3ITGA2BPTPN1MDM2 | |
| SCHEMBL29398995 | 0.90 | L3MBTL1 (0.46) | CASP3PTPN1MDM2KMT2AMDM4 | |
| SCHEMBL21221673 | 0.88 | CASP3 (0.52) | CASP3ITGB3ITGA2BPTPN1MME | |
| SCHEMBL119394 | 0.88 | CASP3 (0.57) | CASP3ITGB3ITGA2BMMEMMEL1 | |
| SCHEMBL3207886 | 0.88 | CASP3 (0.57) | CASP3ITGB3ITGA2BMMEMMEL1 | |
| SCHEMBL119383 | 0.88 | CASP3 (0.57) | CASP3ITGB3ITGA2BMMEMMEL1 | |
| SCHEMBL33377860 | 0.88 | CASP3 (0.57) | CASP3ITGB3ITGA2BMMEMMEL1 | |
| SCHEMBL29400834 | 0.88 | CASP3 (0.57) | CASP3ITGB3ITGA2BMMEMMEL1 | |
| SCHEMBL119588 | 0.86 | MDM4 (0.51) | CASP3ITGB3ITGA2BPTPN1MDM2 | |
| SCHEMBL31714182 | 0.86 | MDM4 (0.51) | CASP3ITGB3ITGA2BPTPN1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198278-A1 | SECO MACROLIDE COMPOUNDS | SELVITA D.O.O. (HR) | 2021-07-01 | — | — | US | disclosed |
| US-10919910-B2 | Seco macrolide compounds | FIDELTA D.O.O. (HR) | 2021-02-16 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198278-A1 | SECO MACROLIDE COMPOUNDS | SEC61B, SEC16A, SEC61A1 | CASP3 1238/4885ITGB3 4743/4885ITGA2B 4787/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | CASP3 2910/4885ITGB3 4415/4885ITGA2B 4478/4885 |
| US-10919910-B2 | Seco macrolide compounds | SEC61B, SEC16A, SEC61A1 | CASP3 1238/4885ITGB3 4743/4885ITGA2B 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.